Radiation Protection Dosimetry Advance Access originally published online on April 7, 2009
Radiation Protection Dosimetry 2009 134(1):38-48; doi:10.1093/rpd/ncp058
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Biokinetic modelling of DTPA decorporation therapy: the CONRAD approach
1 Forschungszentrum Karlsruhe GmbH, PO Box 3640, D-76021 Karlsruhe, Germany
2 Institut de Radioprotection et de Sûreté Nucléaire, BP 17, F-92262 Fontenay-aux-Roses Cedex, France
3 CEA/DSV/CARMIN, 18 route du Panorama, BP6, 92265 Fontenay-aux-Roses, France
4 CEA/DSV/iRCM/SREIT, Laboratoire de Radiotoxicologie, BP 12, 91680 Bruyères le Châtel, France
5 Helmholtz Zentrum München, German Research Center for Environmental Health, Institute of Radiation Protection, Ingolstädter Landstr. 1, 85764 Neuherberg, Germany
6 CIEMAT, Avda Complutense 22, 28040 Madrid, Spain
7 ENEA, Radiation Protection Institute, via dei Colli 16, 40136 Bologna, Italy
8 Federal Office for Radiation Protection, Department of Radiation Protection and Health, 85762 Oberschleissheim, Germany
9 CEA CEA/DEN/DSP, LABM Saclay, Bat. 601, F-91191 Gif-Sur-Yvette, France
* Corresponding author: bastian.breustedt{at}kit.edu
Received December 12, 2008, amended March 12, 2009, accepted March 12, 2009
Administration of diethylene triamine pentaacetic acid (DTPA) can enhance the urinary excretion rate of plutonium (Pu) for several days, but most of this Pu decorporation occurs on the first day after treatment. The development of a biokinetic model describing the mechanisms of decorporation of actinides by administration of DTPA was initiated as a task of the coordinated network for radiation dosimetry project. The modelling process was started by using the systemic biokinetic model for Pu from Leggett et al. and the biokinetic model for DTPA compounds of International Commission on Radiation Protection Publication 53. The chelation of Pu and DTPA to Pu-DTPA was treated explicitly and is assumed to follow a second-order process. It was assumed that the chelation takes place in the blood and in the rapid turnover soft tissues compartments of the Pu model, and that Pu-DTPA behaves in the same way as administered DTPA. First applications of this draft model showed that the height of the peak of urinary excretion after administration of DTPA was determined by the chelation rate. However, repetitions of DTPA administration shortly after the first one showed no effect in the application of the draft model in contrast to data from real cases. The present draft model is thus not yet realistic. Therefore several questions still have to be answered, notably about where the Pu-DTPA complexes are formed, which biological ligands of Pu are dissociated, if Pu-DTPA is stable and if the biokinetics of Pu-DTPA excretion is similar to that of DTPA. Further detailed studies of human contamination cases and experimental data about Pu-DTPA kinetics will be needed in order to address these issues. The work will now be continued within a working group of EURADOS.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Schimmelpfeng Physiology-based modelling in radiation research: the biokinetics of plutonium Radiat Prot Dosimetry, September 1, 2009; 136(2): 74 - 81. [Abstract] [Full Text] [PDF]
|
|